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Abstract
Background: The incidence, progression and related risk factors for recent-onset knee pain (KP) remain uncertain.
This study aims to examine the natural history of KP including incidence and progression and to identify possible
phenotypes and their associated risk factors.
Methods: A prospective community-based cohort of men and women aged 40 years or over within the East
Midlands region (UK) will be recruited via a postal questionnaire from their general practices. The questionnaire will
enquire about: presence and onset of KP; pain severity (0–10 numerical rating scale (NRS)); pain catastrophizing and
neuropathic-like pain (NP) using the painDETECT questionnaires (definite NP scores ≥19–38); risk factors for KP and/
or osteoarthritis (OA) (age, body mass index, constitutional knee alignment, nodal OA, index: ring finger length
(2D4D) ratio); quality of life (SF12); and mental health (Hospital Anxiety and Depression Scale). Clinical assessments will be
undertaken in a sample of 400 participants comprising three groups: early KP (≤3 year’s duration), established KP (>3 years)
and no KP. Assessments will include knee radiographs (standing semi-flexed and 300 skyline views); knee ultrasound (synovial
effusion, hypertrophy, and Doppler activity); quantitative sensory testing; muscle strength (quadriceps, hip abductor, and
hand-grip); balance; gait analysis (GAITrite); and biomarker sampling. A repeat questionnaire will be sent to responders at
years 1 and 3. The baseline early KP group will undergo repeat assessments at year 1 (apart from radiographs) and year 3
(with radiographs). Any incident KP individuals identified at year 1 or 3 questionnaires will have clinical and radiographic
assessments at the respective time points.
Discussion: Baseline data will be used to examine risk factors for early onset KP and to identify KP phenotypes. Subsequent
prospective data, at least to Year 3, will allow examination of the natural history of KP and risk factors for incidence and
progression.
Trial registration: The study was registered on the clinicaltrials.gov portal: NCT02098070) on the 14th of March 2014.
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Background
Knee pain (KP) is a very common musculoskeletal con-
dition and is a leading cause of disability in people aged
over 50 years [1]. Approximately 1 in 4 people in the UK
general population have KP in this age group [2–4],
largely attributed to the presence of underlying knee
osteoarthritis (OA).
The relationship between KP and knee OA is complex
and there is often a marked discordance between struc-
tural joint changes and clinical symptoms [5]. Most
studies focus on late or established OA in people who
may have had pain for many years, and few studies have
examined recent onset KP and “early” clinical OA.
Although people with more persistent and long-standing
troublesome KP are most likely to seek medical atten-
tion and subsequently be labelled as having knee OA [6],
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they often represent the more severe end of the knee
pain and knee OA spectrum [7]. However, KP is the
malady, not knee OA [8]. There is a need to understand
the natural history of knee pain from point of onset
through the fluctuations of the pain experience including
changes in pain type and severity and eventual progres-
sion in some to severe, established daily KP. By under-
standing the risk factors for early onset KP as part of the
spectrum of KP, we have the opportunity to target, treat
and manage KP symptoms earlier and more effectively,
thus potentially preventing the development of a more
painful and functionally impaired joint.
In addition to the deleterious effects of the well-
documented structural changes of knee OA [9–11], early
KP could acquire characteristics of more severe and even
neuropathic-like pain (NP) through central rather than
peripheral mechanisms. For example, increased central
sensitisation of nociceptive pathways where an enhanced
localised pain response spreads from the source to adja-
cent regions may lead to diffuse and more severe regional
KP [12, 13]. Also, there may be ineffective pain inhibitory
mechanisms [14] due to impaired conditioned pain modu-
lation (CPM) that in people with KP and/or knee OA
could cause not only an enhanced pain response but more
diffuse KP and a tendency to other regional body pain. In
fact, over a quarter of older adults with chronic symptom-
atic knee OA present with NP suggesting that neuropathic
mechanisms are contributing to the pain experience [15].
Soni et al [16] reported that KP at baseline was predictive
of a significantly higher risk of subsequent knee symptoms
(9% persistent KP and 29% intermittent KP) and that
those with radiographic OA, symptoms of depression and
multiple regional pain were more likely to have constant
pain while those with inconstant pain reported better
function and quadriceps strength. OA is therefore not a
static disease with pain as its main symptom evolving over
time. It has been suggested that in the early stages KP is
more likely to be mild and intermittent, whereas in the
later stages pain persistence and intensity increase [17].
However, this relationship is not always linear and one in
four people with KP report that pain has been stable or
even improved since its onset [18]. Furthermore, it is pos-
sible that the effect of risk factors on pain will change as
the pain progresses due to changes both in peripheral and
central mechanisms of pain production and modulation.
There are several constitutional and biomechanical
risk factors associated with knee pain such as age,
body mass index, knee injury and knee alignment
[19]. However, apart from structural joint changes,
other local or more general person-specific factors
(for example, pain, genetic polymorphisms or psycho-
social factors) appear likely to influence KP experi-
ence and severity and to associate with different
outcomes [13, 20, 21]. Such factors, however, have
been studied rarely in a general population setting.
Characteristics include pain type (such as NP or
intermittent or constant pain presentations), pain re-
sponses (reduced pain pressure thresholds (PPT)),
psychosocial factors (sleep patterns, anxiety and
depression and pain catastrophising), biomechanical
factors (alignment, proprioceptive ability, and muscle
strength/weakness), genetic factors and pathophysio-
logical biomarkers measured in blood or urine. There-
fore, with the use of a questionnaire and subsequent
clinical assessments, we can examine the relationship
between different phenotypes and pain severity, func-
tional limitation and quality of life. The ultimate goal
is to assist clinicians and health care providers to se-
lect the most appropriate intervention for individual
patients according to their phenotypic characteristics,
to achieve better outcomes with fewer complications
from available interventions.
Objectives:
(1)To better understand the natural history of KP
(2)To determine the prevalence of different
phenotypes of KP (including features suggesting
central pain sensitisation) within the general
population
(3)To determine the relationship between different
phenotypes and pain severity, functional limitation
and quality of life
(4)To identify possible novel associations with each
phenotype
(5)To examine the change of KP and associated factors
over time
Methods
Design
This is a prospective general population cohort study.
The main design is to obtain questionnaire data from
a large proportion of the local adult population aged
40 and over, and to undertake assessments in a sam-
ple of respondents at baseline and then at Year 1 and
Year 3 follow-up. More prolonged follow-up, as well
as additional nested studies, will be considered
subject to scientific review, further ethics committee
approvals and funding.
Ethics
All aspects of this study were approved by the Not-
tingham Research Ethics Committee 1 (NREC Ref:
14/EM/0015) and registered (clinicaltrials.gov portal:
NCT02098070).
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Participants
Inclusion criteria: all men and women aged 40 years and
over, located on the General Practitioner (GP) register,
irrespective of KP status.
Exclusion criteria: inability to give informed consent,
terminal or severe mental illness, and pregnant women
(for clinical assessments only).
Eligibility will be decided by the health professionals in
each general practice using the GP register. The GP
register is a log of patients who have registered with
their local National Health Service practice, who have
lived in the local area (minimum of 24 h) and who have
free access to primary care regardless of nationality or
immigration status. Regional general practices will be
approached via the Clinical Research Network (East
Midlands) including Nottinghamshire and Derbyshire. A
postal questionnaire will be sent to approximately
40,000 adults. The baseline questionnaire will be accom-
panied by a covering letter from their general practi-
tioner (GP) introducing the study and the objectives.
Participants will be able to read about the study and if
willing, complete the questionnaire and return it in an
enclosed pre-paid envelope to Academic Rheumatology
(University of Nottingham) at Nottingham City Hospital.
Return of a completed questionnaire will be taken as im-
plicit consent. At the end of the questionnaire re-
sponders will be asked to indicate separately whether or
not they would be willing to: (1) receive further informa-
tion about a single visit to Academic Rheumatology to
undergo knee radiographs and other assessments; (2) re-
ceive a further similar postal questionnaire in one year’s
time; and (3) to receive further information of other fu-
ture studies related to knee pain and OA.
Baseline
Questionnaire
This will be a community-based questionnaire survey
comprising a sample of the general population of Not-
tingham irrespective of whether they had experienced
KP prior to the time of recruitment. The postal ques-
tionnaire will be developed based on a review of items in
previously published questionnaires [22, 23]. Two pilot
questionnaire versions have been evaluated in volun-
teers, both with and without KP respectively, to identify
any problems with content, language or layout as part of
patient and public involvement (PPI) groups at the
Nottingham University Hospitals NUH Trust.
The questionnaire will be designed to capture detailed
information about the individual, their medical history
and currently known risk factors for knee pain and knee
OA. The questionnaire will include a section on all
current medications (prescribed and over the counter)
and will include supplements, vitamins and alternative
medications. It will also include an open text question
on different treatments tried for knee pain (diet, lifestyle,
exercise, footwear modifications, etc) as well as which
particular treatments have been most helpful for treating
knee pain. The painDETECT Questionnaire (PDQ)
which has been validated against expert physician-
diagnosis of neuropathic pain (NP) in a range of chronic
pain conditions will be chosen to identify NP with a
focus on KP (PDQ scores of ≥13 as possible NP and ≥19
as definite NP) [24]. Participants will be asked whether
they have experienced pain in or around the knee on
most days for at least a month ever and whether they
have experienced any KP during the past month. Pain
experience will be captured using the validated Inter-
mittent and Constant Osteoarthritis Pain (ICOAP)
tool [25–27]. Participants will also be asked to rate
their current pain severity using a numerical rating
scale (NRS) from 0 to 10. A validated screening ques-
tion will be used to determine the presence of current
KP, specifically: “Have you had knee pain for most
days of the past one month?” [28–30]. Current KP, as
well as pain elsewhere, will be captured using a body
pain mannequin [31]. The Pain Catastrophising Scale
(PCS) will be used to quantify pain behaviour and
particularly determine whether participants had an ex-
aggerated negative orientation towards a noxious
stimulus [32]. Individual comorbidities will be self-
reported according to a brief checklist, with data
dichotomised into individuals suffering a specified dis-
ease (e.g. diabetes or fibromyalgia) and those who did
not. An open text question will also be included to
capture any information on any other diagnosed med-
ical conditions not on the checklist. The use of anal-
gesic medication will also be recorded in the form of
any current medication, both prescribed and those
over the counter including vitamins, supplements and
alternative medicines as well as the duration of con-
sumption. Constitutional knee alignment (in early
20’s), current knee alignment and 2D4D finger ratio
(3 patterns) will be self-reported and assessed using
validated line-drawings [19, 33]. In using this instru-
ment, participants separately self-report their current and
early adult life (early 20’s – presumed to be constitutional)
knee alignment as severe varus, mild varus, straight legs,
mild valgus or severe valgus. Those with severe or mild
varus are categorised as having a varus alignment, those
with severe or mild valgus are classed as having a valgus
knee alignment and those with straight legs as neutral
alignment. Nodal OA will be determined using a validated
line diagram [33] and classified as present in those report-
ing nodes on at least two rays of both hands [34]. A sig-
nificant knee injury will be defined as “one which caused
pain for most days for at least a three-month period”. Oc-
cupations will be classed as ‘high risk’ for OA based on
published evidence [35, 36]. Each listed occupation per
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participant will be analysed and the data dichotomised
into high- or low-risk groups. For participants who state
they are unemployed or retired, any previous occupations
will be dichotomised into high or low risk based on job
type (see Additional file 1) and duration (full time or part
time and number of years per position). If no occupations
are listed, then these participants will be categorised as
‘low risk’ in terms of OA. Quality of life will be assessed
using the SF-12 which will produce a physical component
score and mental component score. Anxiety and depres-
sion symptoms will be measured using the Hospital and
Anxiety Depression Scale (HADS) which has been exten-
sively validated. The optimal cut-off score for the presence
of both symptoms is >8 as this has a corresponding sensi-
tivity and specificity of 0.8 [37, 38]. The questions and
their timing are summarised in Table 1.
Clinical assessment
From the questionnaire responders, a sample of par-
ticipants who indicated a willingness to consider
undergoing knee radiographs and other assessments
will be identified. Three distinct groups of partici-
pants (early KP, established KP and no KP) will then
be identified based on their questionnaire responses
on KP duration and severity. They will be sent a
letter of invitation together with a participant infor-
mation sheet. Those who reply registering their inter-
est and who give contact details will undergo an
additional telephone screening prior to being booked
into a single hospital appointment. The inclusion
criteria for clinical assessment are:
i. Participants with recent-onset KP (n = 200) are
defined as mild/moderate and/or intermittent KP occur-
ring for the first time in the past 3 years for most days of
at least one month, unrelated to obvious major trauma.
Once, the early KP group is recruited, participants
from the established KP (ii) and no KP group (iii) will be
age and gender matched to this early KP group (i) using
the following inclusion criteria:
ii. Participants with established persistent KP
(n = 100): defined as KP for over 3 years which has been
moderate (NRS >6) and/or persistent for most days of
the past 3 months, unrelated to obvious major trauma.
iii. Participants with no KP: defined as no KP
(n = 100) within the past 5 years.
Respondents to the questionnaire who report total
knee joint replacement surgery or major prior knee
injury will be excluded - only those with spontaneous
(“primary”) KP will be selected for groups (i) and (ii).
Participants will be asked to attend their hospital
appointment fasting since the previous evening (for pur-
poses of blood and urine biomarker collection).. They
will be verbally informed about the assessments by
trained research personnel, regarding the nature and
purpose of the study, invited to voice any questions or
concerns, and given time to decide whether or not to
participate. Written informed consent will then be
obtained from all study participants prior to any assess-
ment (one copy being given to the participant) and all
data will be treated as confidential and anonymised.
Following arrival at Academic Rheumatology and after
giving written informed consent, the research professional
will collect a fasting urine sample and a 10 ml sample of
blood via ante-cubital venepuncture. These samples will
be analysed for markers of collagen degradation (e.g. uri-
nary collagen type II crosslinks (CTX-II)) which is predic-
tive of OA progression and markers of generalised
inflammation such as serum levels of c-reactive protein
(CRP). Other inflammatory markers which are correlated
to severity of OA pain, specifically the pro-inflammatory
cytokines (e.g. IL-1, IL-6, TNF alpha and the resolvin pre-
cursor 12-HDHA) will also be analysed [39]. The research
professional will then administer a short structured inter-
view concerning the participant’s recent medical history
and current KP status, in case these have altered since
completing the baseline questionnaire. They will also
administer the General Practice Physical Activity Ques-
tionnaire (GPPAQ) which takes less than a minute to
complete and allows categorisation of participants into
four categories of physical activity: active, moderately
active, moderately inactive and inactive.
A number of clinical assessments will then be under-
taken in the following sequence:
i) Hand grip strength: Each participant will be assessed
using a JAMAR hydraulic hand dynamometer
(Lafayette Instruments). Participants will be
positioned sitting upright in a stable four-legged
chair (no armrests) with thighs horizontal and at
90o. The assessed arm will be bent with the upper
arm vertical, lower arm horizontal, and elbow tight
into the waist and the non-assessed arm placed re-
laxed in their lap. The grip device will then be placed
into the participant’s hand and they will be asked to
squeeze the device momentarily as hard as possible
and then release their grip. This will be performed
three times on their dominant hand and the mean of
the three readings will be recorded.
ii) Maximum voluntary quadriceps muscle strength:
The maximum voluntary quadriceps contraction will
be assessed for each participant in a standard
fashion using the ‘Nicholas Manual Muscle Tester’
(Lafayette Instruments). The participant will be
positioned sitting upright on a stable flat surface (no
armrests) with thighs horizontal and knees at 90o
with their feet raised off the floor. The Muscle
Tester will then be positioned at the bottom of the
participant’s tibia just above the ankle and they will
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Table 1 Measurement of domains and data collection time points for questionnaire data. (* Clinical assessments will be conducted
in a sub-sample of participants at baseline with follow-up assessments at Year 3 for all participants and incident KP cases recruited
at Year 1 and Year 3)
Section Domains Questions & Instruments Included Baseline 1 year 3 years
Demographic & Occupation
Data
Date of birth, Gender, Height & Weight & list of main occupations
(duration and whether it was part time or full time)
Medical & Medication
History
Diagnosis of any comorbidities such as diabetes, stroke, fibromyalgia.
Trauma or significant injury to the lower limbs.
All current medication including supplements and alternative medications.
Knee Pain Knee Pain presence, diagnosis of knee OA, any surgical interventions,
any treatments for knee pain,
ICOAP (Intermittent and Constant OA Pain)
Pain Detect Questionnaire
Knee Alignment Current and Constitutional alignment using line drawings
Hands 2D4D ratio; OA nodes; family history of OA nodes and knee or hip joint
replacement
Body Pain Body Pain Mannequin for current body pain
Quality of Pain (severity)
Psychosocial Factors Hospital Anxiety & Depression Score
Sleep scale from Medical Outcomes Survey (from Year 1)
Conscientiousness Test (from Year 1)
Fibromyalgia Mannequin (from Year 1)
Life Orientation Test (LOT) (from Year 1)
Quality of Life SF – 12
Illness Attitude Scale
Pain Catastrophising Scale
Clinical Assessments*
Blood & Urine Sample Collection Fasting Biomarker Sample collection
Ultrasound
Quantitative Sensory Testing
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be asked to push against it as hard as possible in an
attempt to raise their lower leg forwards, with
resistance provided by the research professional.
This will be repeated three times on each leg and
the mean value for each side recorded.
iii)Maximum voluntary hip abductor muscle strength:
The maximum voluntary hip abductor muscle
contraction will be assessed for each participant in a
standard fashion using the ‘Nicholas Manual Muscle
Tester’ (Lafayette Instruments). The participant will
be positioned on a clinic couch lying on their side
with the lower leg bent for stability and the upper
leg held out straight. The Muscle Tester will then be
positioned above the ankle of the upper leg and the
participant asked to push against it as hard as
possible in an attempt to raise their leg up towards
the ceiling with resistance provided by the research
professional. This will be repeated three times on
each leg and the mean value for each side recorded.
iv)Balance: Static balance and postural sway either in
the medial-lateral or antero-posterior direction will be
assessed using the RS Scan force plate. The participant
will be asked to stand on the plate looking straight
forward for 30 s in two conditions: first with their eyes
open and then with eyes closed. Medial-lateral,
antero-posterior and total sway will be recorded.
Mechanical adaptions in loading are a facet of early
knee OA development and progression. Although
people with established knee OA demonstrate
reduced balance and increased postural sway, these
changes may not be evident in the early stages [40]
Establishing baseline balance parameters and assessing
how these may alter over the course of the cohort
study timeline are relevant to understanding the
natural history of KP and for early interventions that
may delay or prevent worsening symptoms.
v) Ultrasound (US): Both knee joints will be imaged
using a Toshiba Aplio SSA-770A machine with a
multi-frequency (7–12 MHz) linear array transducer.
The same equipment and software will be used dur-
ing the whole study. The assessment will be per-
formed with knee flexion of approximately 20–30°
and will include the supra-patellar recess, medial
and lateral tibio-femoral spaces. US detected changes
will be defined according to definitions accepted by
the OMERACT-7 Group [41]. The maximal synovial
thickness and effusion depth will be measured in
millimetres using the longitudinal axis. These abso-
lute values will be dichotomised as absent (<4 mm)
or present (≥4 mm) according to the EULAR Re-
search Group recommendation [42]. A Power Dop-
pler assessment will focus on areas of synovial
hypertrophy. A Positive Power Doppler signal which
provides information on vascularity will record this
feature as absent or present. Only one value per joint
will be recorded for each US feature (maximum
value across three scanned areas for all participants).
It has been previously reported that overall agree-
ment between synovial hypertrophy detected in
these three areas of the knee and synovitis detected
using the arthroscopy (“gold standard”) was 97%
with non-significant difference in sensitivity between
three compartments [43].
vi)Gait Analysis: Dynamic gait analysis will be
performed using the GAITrite portable platform
which measures temporal and spatial gait
parameters. Participants will be instructed to
complete six walks at a natural comfortable pace in
their own footwear in a gait laboratory starting a
metre before and after the mat to allow a constant
speed to be recorded. The six walks will be recorded
and will be averaged for final analysis [44]. This
Table 1 Measurement of domains and data collection time points for questionnaire data. (* Clinical assessments will be conducted
in a sub-sample of participants at baseline with follow-up assessments at Year 3 for all participants and incident KP cases recruited
at Year 1 and Year 3) (Continued)
Section Domains Questions & Instruments Included Baseline 1 year 3 years
Radiographs Bilateral radiographs consisting of PA view of the tibiofemoral compartment
and skyline view of the patellofemoral compartment using a Rosen template
(standardised views).
Gait Assessment Gaitrite and RS Scan for walking speed, cadence, step length, step width and
static and dynamic balance
Muscle Strength JAMAR hand dynomometer & Nicholas Muscle Testers for hand grip strength
and quadriceps/ hip abductor strength respectively.
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includes information on walking speed, cadence,
step length, step width and dynamic balance
measures (centre of pressure).
vii)Quantitative Sensory Testing (QST): Participants will
be invited to participate in non-invasive QST which
assesses sensitivity to standardised stimuli. This
comprises assessment of mechanical pressure pain
thresholds (PPT) at baseline and year 1 using a
hand-held pressure algometer (Somedic AB,
Sweden) that is connected to a computer (HP
ProBook 4520 s). The algometer will consist of a rod
with a circular end (1cm2) that is placed perpendicu-
lar to the skin and pressure applied at a gradually
increasing rate (standardised rate set at 30 kPa/s)
until the participant indicates that the sensation has
changed from pressure to pain by pressing a button.
The algometer is then immediately taken off the
skin. Participants will be familiarised with the test by
the research professional who uses the algometer to
apply gradual pressure to a fingernail of the dominant
hand. As soon as this pressure elicits pain, participants
will be asked to press a button to stop the test. This fa-
miliarisation procedure is standardised and conducted
twice for all participants prior to the PPT test
commencing.
One cycle of PPT testing will involve the algometer
being used on the following 7 anatomical sites: the
sternum (3 cm caudal to the sternal notch); the medial
tibiofemoral joint line located medial to the patellar
ligament of both knees; the lateral tibiofemoral joint line
located lateral to the patellar ligament of both knees;
and the proximal shins (both legs) [45]. These sites were
chosen to avoid influence of pain from other tissues, for
example, muscle, ligaments and tendons. We agree that
“muscle-deep pain” is widely addressed using QST ap-
proaches in studies of this nature, however, there is little
experimental representation of the “deep pain sensation”
– a core characteristic of knee pain associated with OA.
PPTs on such bony surfaces have been shown to be re-
producible and recommended for experimental tests of
evoked bone-associated pain. Thus, our approach will
provide evidence specific to the “deep pain sensation”
across localized, distal and remote sites in our study par-
ticipants. The PPT cycle will be repeated three times
with a 2 min rest period in between each cycle. The PPT
will be repeated at follow-up (year 3).
In addition to PPT, temporal summation (TS) also
known as wind-up ratio and mechanical sensitivity will be
assessed at follow-up (year 1) using a 256 millinewton
(mN) weighted pinprick stimulator [24, 45]. The stimula-
tor will be applied perpendicular to the skin, 2 cm distal
to the infero-medial border of the patella of the knee to
detect a sensation of sharpness or pain. The participant
will be asked to rate their pain on an NRS of 0–100 where
0 indicates no pain or sharpness and 100 indicates the
most intense pain or sharpness. This rating will be re-
corded. The stimulator will then be applied to the same
site 10 times repeatedly at a rate of 1 per second. At the
end of 10 pinpricks, participants will be asked to rate the
pain or sharpness using the NRS and this is then recorded.
The entire procedure will be repeated twice. The TS will
be calculated as the mean pain rating of both series of re-
petitive pinprick stimuli divided by the mean pain rating
of both baseline NRS measures. The mechanical sensiti-
vity will be calculated as the mean pain rating of both
baseline NRS measures.
Participants will be familiarised with the tests first on
their non- or least affected knee. The tests will then be
conducted using their worst or most affected knee. The
TS test and mechanical sensitivity test will be repeated
at Year 3.
viii)Radiographs: Bilateral tibio-femoral and patello-
femoral radiographs will be taken using a standardised
protocol (standing posterior-anterior (PA) and skyline
views) and scored by two specifically trained raters
(GSF and AS). A Perspex Rosenberg template with
lead beads will be used for the standing PA view to
standardise the degree of knee flexion, foot rotation
and magnification [46]. PA radiographs will be taken
with the patient facing the x-ray tube while standing
on the Rosenberg template and leaning forwards with
their thighs touching the anterior aspect of the
apparatus, the x-ray beams passing from the posterior
aspect through to the anterior aspect of the knee.
Variable jigs will be used for the skyline view to obtain
300 of knee flexion with the participant lying in a
reclined supine position on a couch. Grading of
radiographs for changes of OA will include [1] the
summated Kellgren and Lawrence (KL) score and [2]
the Nottingham logically devised line drawing atlas
(NLDA) for individual scoring of osteophyte (0–5)
and joint space width (−1 to +5, using sex-specific
atlases) for each medial tibio-femoral (TF), lateral TF
and patello-femoral (PF) compartment similar to
previous published epidemiological studies [23].
The flow of participants through the study is depicted
in Fig. 1.
Year 1 follow-up
Questionnaire
Of those participants who indicated interest and consent
to follow-up at baseline, a follow-up postal questionnaire
will be issued in year 1. The year 1 questionnaire will
follow the format of the baseline questionnaire with
some changes. We will not re-administer questions on
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constitutional risk factors such as early knee alignment
and 2D4D ratio since these would not change from
baseline. We will add a set of questions on sleep from
the Medical Outcome Survey. A modified body pain
mannequin (see Additional file 2) with two questions on
symptom severity and widespread pain index will also be
included to allow scoring of fibromyalgia as a diagnosis
with binary (present/absent) classification using a vali-
dated tool [47]. The questionnaire will also be updated
to include the Life Orientation Test (LOT) which
evaluates a lack of positive beliefs as well as low negative
beliefs [48] and a short item test on conscientiousness
(Big 5) [49]. We will also add an illness perceptions
questionnaire to measure patient’s belief about their KP
[50]. These validated tools will be included as they con-
tribute to the psychosocial aspects of the disease and
could be predictors of patient and clinical outcomes. All
questionnaire changes will be approved following feed-
back and review from PPI groups and subsequently,
submitted for NREC approval.
Clinical assessment
From the responders to the Year 1 questionnaire, any
new cases of early KP (incident KP for most days in a
month for the past 12 months) will be identified and in-
vited for clinical assessments as per the baseline
protocol. It is estimated that the new incident KP cases
may number from n = 70–110 from the Year 1 question-
naire mail-outs (based on an annual incidence of 3.2%)
[23].
For those early KP participants who attended the base-
line appointment, there will be repeat assessments of
muscle strength, gait, balance and ultrasound. The PPT
assessments will be done on the most painful knee of
participants with KP. For those who have an equal pain se-
verity in both knees, the right knee will be assessed. The
PPT protocol will also be complimented by TS testing. TS
or windup will be used to assess central sensitivity and
characterise central pain processing abnormalities by
measuring how pain is perceived (using a NRS) once
repetitive stimuli (weighted pinprick) is applied [51, 52].
Year 3 follow-up
A follow-up questionnaire will also be mailed out at
Year 3. Only the early KP group (including incident KP
identified at year 1) will be re-assessed at year 3 for
change of outcomes. In addition, people without KP at
baseline or year 1 but reporting KP at year 3 will be con-
sidered as new incident KP cases and will be assessed
clinically (including knee radiographs) as per the base-
line protocol.
Fig. 1 Recruitment Flowchart for KPIC. Questionnaire: administered at baseline, Year 1 and Year 3 for all who indicated interest and consent to
follow up at baseline. Clinical Assessments: will be repeated for early Knee Pain (and new knee pain cases from the no knee pain groups). No
repeat assessments will be undertaken for the establish Knee Pain group
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Sample size
The sample size calculated was based on the primary
objective of this study: to examine the natural history of
KP within a community setting which involves the re-
cruitment of as many knee pain positive and knee pain
negative individuals with detailed exposure data cap-
tured from the questionnaire. The subsequent objectives
are to examine the incidence, progression and associated
risk factors.
1. Source population: 40,000 questionnaires will be
sent via post with a target of recruiting 10,000
participants (response rate 25%), which will form the
source population of this study. Based on our
previous studies, this would give 2500 people with
knee pain (KP +) and 7500 people without knee pain
(KP -). The sample size is 10 times larger than the
subsequent sample size calculations for incidence,
progression and risk factors of KP.
2. Sample size for incidence and progression of KP: A
sample of 730 participants will allow the detection of
3% (±1%) annual incidence of knee pain in a
population over the age of 4524 at power of 90%
(alpha 0.05, two-sided). This sample will also be able
to detect a 14% occurrence of knee pain progression
(worsening) (±5%) 24 at a power of 90% (alpha
0.05). An annual drop off rate of 30% plus 3% annual
incidence rate of KP is excluded from the source
population.
3. Risk factors: A logistic regression model was used to
calculate the sample size for one primary risk factor and
multiple covariates. According to the annual incidence
of 3% KP24 and an OR of 2 associated with overweight/
obese [53] and assuming a multiple correlation
coefficient of other covariates is 0.3, 702 participants are
required for this risk factor analysis to give a power of
90% (alpha 0.05). For progression (i.e., 14% KP
worsening), however, 203 participants are required.
Sub-studies sample sizes
Sample size for NP: According to a NP prevalence of
28% (±8) based on a previous community population
sample [15], 85 participants are required to yield a
power of 90% (alpha 0.05).
Sample size for PPT: According to a difference of 0.32
SD (standard deviation) on pressure pain threshold (PPT)
between established KP (group ii) and No KP [54] and
0.16 SD between early KP and no KP, 600 participants are
required for a three-group comparison with an unbal-
anced (400:100:100 for the “Early KP”, “Established KP”
and “No KP”) one-way ANOVA design. This unbalanced
design will be applied to keep the main interest on early
KP and its subsequent follow-up for progression.
Sample size for US: Data from a previous Nottingham
community based case control study was used and this
study [55] comprised four groups: people with KP and
radiographic changes (Kellgren and Lawrence (K&L)
score ≥ 2); people with KP without radiographic
changes; people with no KP but radiographic changes;
and people with no KP and normal x-rays. We used KP
only as “early KP”, KP plus radiograph changes as
“established KP” and combined the two no KP groups to
form the control. We then calculated standardised effect
sizes for each case group versus control based on
means/SD (1.06, 2.02 and 0.96, respectively). The total
sample size required is 80 (group balance 40:20:20)
which will yield 90% power with 5% type I error for this
unbalanced multiple group case-control study.
Statistical analysis
Questionnaire and clinical assessments
For baseline questionnaire data, prevalence of KP and
type of KP (e.g., NP) will be estimated. Risk factors asso-
ciated with KP and different types of KP (e.g., NP) will
be examined. Odds ratio (OR) and 95% confidence inter-
val (CI) will be given to present the association and lo-
gistic regression model will be used to adjust for
confounding factors such as age, gender, body mass
index and pain severity.
For the baseline clinical assessment data, the overall dif-
ference among three groups categorised according to KP
status (Early KP, established KP and controls) will be
analysed using multinomial logistic regression. This is an
extension of binary logit regression when the categorical
dependent variables have more than two response cat-
egories. The “No KP” group will be chosen as a reference
(base). As cases and controls will be frequency matched
(by age and gender) unconditional logistic regression ana-
lysis will be chosen. The odds ratio (OR) and 95% CI will
be used to measure an association. All models will be ad-
justed for potential confounding factors and checked for
interactions and collinearity as appropriate.
The loss to follow-up rate (from baseline to Year 1
and then to Year 3) can be measured in terms of vari-
ables such as age, gender and severity of symptoms and
in order to mitigate the differential bias, a multiple
imputation model alongside sensitivity analyses will be
considered. For follow-up data, incidence and progres-
sion of KP will be estimated. Logistic regression model
will be used for year 1 and other single time point
follow-up analysis. The Kaplan–Meier method will be
used to generate survival curves and a log-rank test
will be used to examine the time-to-event outcomes
for multiple follow-up data. The proportional hazards
assumption will be examined graphically using the
Kaplan–Meier method for each risk factor. The Cox
proportional hazards model will be used to calculate
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the hazard ratio (HR), adjusted for confounding
factors such as age, gender and BMI. Differences be-
tween the study population; those invited to participate
and responders will be tested using a one-way analysis of
variance (ANOVA) with post hoc Bonferroni correction.
Statistical significance will be inferred when P value is less
than 0.05, or when the 95% confidence interval (CI) does
not include unity.
KP phenotypes
We hypothesise that phenotypic markers representative
of underlying pain mechanisms can be identified using
self-report questionnaire items. Groups of questionnaire
items will be entered into an exploratory structural
equation model (ESEM) in order to identify underlying
(latent) constructs (e.g. depression) being measured.
ESEM also specifies the strength of association between
each item and the underlying construct. Items showing
the strongest association (p < 0.05) to each underlying
construct will be shortlisted for inclusion within a devel-
oping tool which aims to classify underlying pain mecha-
nisms in individuals reporting knee OA pain. ESEM will
be conducted using MPlus 7.
Reproducibility
For reproducibility of assessments, we will use the
kappa-statistic for categorical data (x-rays and dichotom-
ous US data) and the concordance correlation coefficient
for continuous data. The magnitude of agreement on
categorical data will be measured using the unweighted
kappa statistic (for binary) or the weighted kappa statis-
tics (for ordered categorical data) [56]. A numerical rat-
ing of kappa will be interpreted according to accepted
criteria (0–0.2: slight; 0.2–0.4: fair; 0.4–0.6: moderate;
0.61–0.8: substantial; 0.81–1.0: almost perfect) and 95%
confidence intervals will be reported [57].
All analyses will be undertaken using Stata Statistical
Software: Release 13 (StataCorp. 2013, College Station,
TX: StataCorp LP). P values less than 0.05 will be con-
sidered significant.
Discussion
A population-based prospective cohort study is needed
to determine the natural history of KP, involving affected
and unaffected people at baseline, to examine the inci-
dence, progression, different KP phenotypes and associ-
ated risk factors and outcomes. Results from our study
can provide an insight into possible pain phenotypes
according to self-reported factors such as intermittent
versus persistent KP, localised versus generalised KP,
qualitative descriptors of KP that suggest central sensi-
tisation, and presence of multiple regional pain.
The advantages of KPIC in comparison with other
studies published so far include the focus on the entire
spectrum of knee pain, the long follow-up duration
(three years in the first instance), the repeated measures
of both exposures and outcomes at several time points
and the battery of clinical assessments in people with
early KP, no KP and established KP. It is important that
the KPIC study population is representative of the
general population (See Additional file 3). The inclusion
criteria is set slightly younger (40 years and above) than
other population cohorts such as the Genetics of OA
and Lifestyle study (45 years and over) and the British
National Survey (55 years and over) in order to capture
more participants with any symptoms or radiographic
signs of early OA as opposed to established KP which
has already been extensively researched but mainly in
people over 50 [58–62].
The expected response rate of 25% is lower than
the mean response rate of 60% for postal surveys
published in medical journals [63]. However, this is
based on previous surveys to the community in Not-
tingham and this rate could be improved with the use
of reminder letters and an accompanying postal ques-
tionnaire. The response rate could also be improved
with the use of financial incentives, however, there is
limited evidence to support this [64]. In order to re-
tain participants through the course of the KPIC
timeline, the authors will ensure timeline question-
naire reminders (4–6 weeks) post initial questionnaire
mail out as well as annual newsletters with updates
on study progression such as successful recruitment
to a sub-study and preliminary findings.
There are some limitations to the study design of
KPIC. Firstly, being a questionnaire-based cohort study,
the design is prone to a number of biases including re-
sponse bias (participants with KP more likely to respond
to the questionnaire) and recall bias (participants with
KP may recall events and exposures more accurately
compared to those without KP). However, the question
on KP is very specific and focused on any symptoms in
and around the knee for most days of at least one month
in the previous 12 months which is the ‘gold standard’
for epidemiological research studies [30]. Current knee
pain was defined as pain in or around the knees for most
days of the past one month for incident knee pain. This
was different from early onset knee pain which was
defined as knee pain (ever or current for most days of at
least a month) in the past 3 years. However, due to the
transient nature of knee pain, it is possible that the base-
line questionnaire might not allow us to correctly iden-
tify participants as being knee pain positive or knee pain
negative (misclassification bias). A self-reported ques-
tionnaire approach also ensures the absence of interview
bias from the study results [23]. Secondly, although the
questionnaire cohort is large (n = 40,000), the clinical
subset cohort is relatively small (n = 400). There may be
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limitations to using multiple adjusted effect estimates
that have all been taken from a single logistic regression
model. A bias otherwise known as the table 2 fallacy
could occur where the interpretation of the confounder
estimates may be different than for the exposure effect
estimates [65]. Thirdly, there is a selection bias associ-
ated to a potential differential loss to follow-up in the
group with moderate-severe pain or participants who
are frail. The responders and non-responders will be
compared at Year 1 and Year 3 in order to measure and
subsequently adjust for this bias.
Knowledge obtained from this proposed cohort
study could be important for understanding the nat-
ural history of KP, including incidence, in a
community-based population setting. Currently, we
are unaware of any other population-based cohort
established for people at risk for KP, therefore this is
the first cohort to cover the full natural history from
no KP to KP, then to the outcomes of KP. In
addition, we are not only interested in KP severity
but also KP phenotypes. Identifying specific subgroups
or phenotypes of people with KP and possible novel
associations with each phenotype are important as it
may help to develop specific individualised treatment
or management strategies. The cohort will also help
us to understand the implications of central sensitisa-
tion versus localised pain features and use this to
improve the diagnosis, treatment and management of
KP and knee OA in the general population.
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